Anaveon: Re-focusing IL-2 to fuel anti-cancer immunity

Anaveon, a Basel-based immuno-oncology biotech, has recently concluded a $35 million series A round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with a non-dilutive loan from BaseLaunch in 2017, and in 2018 raised seed money from the UZH Life Sciences Fund.

The proceeds are intended for advancement of anti-IL-2 antibodies, which promote the proliferation of a class of immune cells capable to reject cancers without promoting the proliferation of cancer protective immune cells. Now the aim is to manufacture the antibodies in the appropriate quality standards and then test them in clinical studies for safety and efficacy in melanoma, kidney and lung carcinoma and other cancers. The clinical effect of the Anaveon compounds will be to increase the patient’s immune response against tumors.

This Life Science event will have Dr. Andreas Katopodis, co-founder and CEO of Anaveon, talking about the story of the company, their plans for the future and their approach to developing therapeutics that fuel anti-cancer immunity.

When: 12.12.2019, 18:30-20:00
Where: Markthalle Basel, Steinentorberg 20, 4051 Basel



18:30     Door opening

19:00     Introduction

19:05     Dr. Andreas Katopodis, CEO Anaveon

19:35     Q&A

20:00    Networking Apero

Participation to the event is free of charge; however, your registration by 11th December 2019 is kindly required.

About the speaker

Andreas Katopodis studied molecular biology and immunology. After five years at the Georgia Institute of Technology in Atlanta, he moved to the Ciba Geigy Zentrale Forschungslaboratorien in Basel, doing research on immune cell trafficking. With the creation of Novartis, he moved to the Novartis Autoimmunity, Transplantation and Inflammation group where he was involved in many aspects of early to late drug development for immune mediated diseases, such as solid organ transplantation and autoimmunity. In 2018, he co-founded Anaveon to pursue the development of immune stimulating pathways for the rejection of tumors.